Cargando…

Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer

BACKGROUND: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. METHODS: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Qing, Fan, Tao, Zhang, Boyou, Wang, Wei, Xu, Yao, Hu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248445/
https://www.ncbi.nlm.nih.gov/pubmed/25421010
http://dx.doi.org/10.1186/s12931-014-0149-3
_version_ 1782346804262600704
author Geng, Qing
Fan, Tao
Zhang, Boyou
Wang, Wei
Xu, Yao
Hu, Hao
author_facet Geng, Qing
Fan, Tao
Zhang, Boyou
Wang, Wei
Xu, Yao
Hu, Hao
author_sort Geng, Qing
collection PubMed
description BACKGROUND: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. METHODS: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs. RESULTS: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups. CONCLUSIONS: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.
format Online
Article
Text
id pubmed-4248445
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42484452014-12-02 Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer Geng, Qing Fan, Tao Zhang, Boyou Wang, Wei Xu, Yao Hu, Hao Respir Res Research BACKGROUND: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. METHODS: In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs. RESULTS: ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups. CONCLUSIONS: In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results. BioMed Central 2014-11-25 2014 /pmc/articles/PMC4248445/ /pubmed/25421010 http://dx.doi.org/10.1186/s12931-014-0149-3 Text en © Geng et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Geng, Qing
Fan, Tao
Zhang, Boyou
Wang, Wei
Xu, Yao
Hu, Hao
Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
title Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
title_full Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
title_fullStr Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
title_full_unstemmed Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
title_short Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
title_sort five micrornas in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248445/
https://www.ncbi.nlm.nih.gov/pubmed/25421010
http://dx.doi.org/10.1186/s12931-014-0149-3
work_keys_str_mv AT gengqing fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer
AT fantao fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer
AT zhangboyou fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer
AT wangwei fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer
AT xuyao fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer
AT huhao fivemicrornasinplasmaasnovelbiomarkersforscreeningofearlystagenonsmallcelllungcancer